Posted by Michael Wonder on 18 Apr 2023
CSL Behring receives FDA approval for Hizentra (immune globulin subcutaneous [human] 20% liquid) 50 mL pre-filled syringe
18 April 2023 - Hizentra is the first and only immune globulin available in pre-filled syringes, offering those living with primary immunodeficiency or chronic inflammatory demyelinating polyneuropathy a simple, convenient and ready to use option.
CSL Behring today announced the US FDA approved a 10 g/50 mL pre-filled syringe for Hizentra (immune globulin subcutaneous [human] 20% liquid).
